JP2006022101A - Composition containing anti-acne agent and method for using the same - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a composition containing an anti-acne agent, an antimicrobial agent and a lactic acid salt. <P>SOLUTION: The present invention provides a composition containing an anti-acne agent, antimicrobial agent and a lactic acid salt and a method for using the composition. The anti-acne agent is selected from a group consisting of salicylic acid, benzoyl peroxide, sulfur, retinoic acid, azelaic acid, clindamycin, adapalene, erythromycin, sulfacetamide sodium and a combination thereof. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

  Acne is a skin disease that often produces embarrassing pimples. Consumers have used topical anti-acne agents such as salicylic acid and benzoyl peroxide to treat acne for many years. Topical anti-acne agents usually exfoliate the skin and / or kill bacteria on the skin surface. Such anti-acne agents are often effective in treating acne pimples that alleviate the symptoms of acne and usually take days to weeks to cure. Anti-acne agents are also often ineffective in treating acne before appearance.

  Pigmental abnormalities such as post-inflammatory pigmentation (PIH) and scarring are often caused by acne, pseudochorionic folliculitis (FEB), and other follicular diseases. Although more common in darker types of skin, post-inflammation pigmentation can occur in any type of skin. When PIH or deep pigmentation occurs, the skin becomes non-smooth, lacks transparency and appears to be not flat.

  In order to solve the above-mentioned problems, a composition comprising an anti-acne agent, an antibacterial agent, and lactate is provided.

  The present invention relates to a composition comprising an anti-acne agent, an antibacterial agent, and lactate. The present invention also relates to a method for treating hair follicle diseases such as acne, wherein the composition is applied to the skin area in need of treatment. The present invention also relates to a method of applying a composition to a skin area that requires treatment so that the appearance of skin pores and sebum is not noticeable. The present invention also relates to a method for smoothing the skin by applying the composition to the skin portion requiring treatment to adjust the skin tone.

  Other features and advantages of the invention will be apparent from the following detailed description of the invention and the appended claims.

  There is provided a composition comprising an anti-acne agent, an antibacterial agent, and lactate for use in hair follicle diseases such as acne. Also provided is a method of applying a composition to the skin area that requires treatment so that the appearance of skin pores and sebum is not noticeable.

  One of ordinary skill in the art will be able to best utilize the invention based on the present disclosure. It should be understood that the following specific embodiments are merely examples and do not limit the present disclosure in any way.

  Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition, all publications, patent applications, patents, and other references are incorporated herein by reference. Unless otherwise specified, all percentages are weight percent (w / w).

  As used herein, “topical application” means applying or spreading directly to the outer skin with an applicator such as a wipe, puff, roller, spray or the like.

  As used herein, “superficially acceptable” means that a compound or composition is used in contact with tissue (eg, skin) without undue toxicity, incompatibility, instability, irritation, and allergic reactions. It means that it is suitable for. This term is not limited to compounds / compositions that only describe cosmetics (eg, ingredients / products can be used as drugs).

  As used herein, a “safe effective amount” refers to an amount sufficient to treat acne that is not so severe as to cause severe side effects.

  “Promotion” refers to promotion, promotion, or marketing. Examples of promotions may include, but are not limited to, written, video, or verbal statements for products containing the composition, or statements in stores, magazines, newspapers, radio, television, and the Internet. . The composition of the present invention comprises acne, rosacea, hyperlipidemia, seborrhea, sebaceous hyperplasia, follicular rash, acne tick follicular infection (folliculitis, staphylococcal impetigo acne necrosis, and pseudochorionic folliculitis ), Follicular keratosis, follicular keratosis, catfish skin, follicular ichthyosis, hair loss, follicular dysplasia, hirsutism, oily skin, and hypertrichosis Useful for the treatment of The term “treating” or “treatment” as used herein refers to the treatment (eg, alleviation or elimination and / or cure of symptoms) and / or prevention or suppression of a medical condition (eg, a skin condition).

  The composition of the present invention adjusts the skin tone in need of treatment (such as thinning the dark part of the skin), smoothes the skin (reduces the unevenness of the skin), reduces the production of sebum, And is useful in reducing the appearance of skin oils, shine and / or pores in need of treatment. Examples of skin in need of such treatment include, but are not limited to, excessively pigmented skin (such as freckles, post-inflammatory pigmentation (PIH), or pigmented scars), rough skin, oily skin, Or the skin where a pore is conspicuous can be mentioned.

  In one embodiment, the composition is used for the treatment of acne including, but not limited to, spotted acne, pimple acne, pre-emergent pimple, blackhead, and / or whitehead treatment and prevention. “Pre-appearance pimples” are, for example, inflammatory hair follicles that cannot be confirmed on the skin surface with the naked eye as lesions. In one embodiment, the appearance of acne (eg, the size and / or appearance of acne lesions and / or comedones) is reduced within 8 hours, such as within 4 hours.

  In one embodiment, the present invention relates to a topical composition comprising an anti-acne agent. An “anti-acne agent” is a compound approved by the US Food and Drug Administration for topical treatment of acne. Examples of anti-acne agents include, but are not limited to, salicylic acid, benzoyl peroxide, sulfur, retinoic acid, Candida bombicola / glucose / methyl rapeseedate ferment, peat water , Resorcinol, fine sand, peat, permethin, azelaic acid, clindamycin, adapalene, erythromycin, sulfacetamide sodium, and combinations thereof. In one embodiment, the amount of anti-acne agent in the composition is from about 0.01 wt% to about 10 wt%, such as from about 0.1 wt% to about 5 wt%, or about 0.1 wt% relative to the total weight of the composition. 5 wt% to about 2 wt%.

  In one embodiment, the composition of the present invention comprises a hair restorer. A “hair restorer” is a compound that promotes hair growth. Examples of hair restorers include, but are not limited to, minoxadil, spironolactone, cyproterone acetate, azelaic acid, buserelin, bicalutamide, cromakalim, cyclosporine, aminoglutethimide, diazoxide, phenytoin, estradiols, flutamide, prezatide copper , Incoterone, leuprolide acetate, ketoconazole, pinacidil, progesterone, finasteride, retinoic acid, turosteride, vitamin E, niacin (vitamin B3), pantothenic acid (vitamin B5), pyridoxine (vitamin B6), vitamin Vitamins and minerals such as B12, vitamin C, vitamin K, biotin, inositol, zinc, copper, cysteine, methionine, coenzyme Q10, linseed oil, Mention may be made of essential fatty acids such as primrose oil and fish oil, herbal extracts such as ginkgo biloba, and combinations thereof.

  In one embodiment, the composition of the present invention comprises a hair growth inhibitor. “Hair growth inhibitor” is a compound that weakens hair growth and / or hair growth. Examples of hair growth inhibitors include, but are not limited to, antiandrogen sterol, dipeptide-N- (, derived from seeds of efflornitine hydrochloride, soy extract, saw palmetto (selenoalpense), and / or pumpkin (pepo pumpkin) Carboxymethyl) phenylalanyl-β-alanine compound, 3-deazaneplanocin, nitric oxide synthase inhibitors such as NG-methyl-L-arginine, 6-diazo-5-oxonorleucine ( Mention may be made of glutamine metabolism inhibitors such as I) and combinations thereof.

  In one embodiment, the composition of the present invention comprises an antimicrobial agent. An “antibacterial agent” is a compound that kills microorganisms or prevents or inhibits the growth and growth of microorganisms. Examples of antibacterial agents include, but are not limited to, ethanol, propanol, betaines, benzalkonium chloride, benzethonium chloride, lauric arginayte, sugarquat, methylbenzethonium chloride, cetylpyridinium chloride, 2,4,4 ′,-trichloro-2-hydroxydiphenyl ether (triclosan), parachlorometaxylenol (PCMX), rhodopropynyl butyl carbamate, diazolidinyl urea, chlorhexidine digluconate, chlorhexidine acetate, chlorhexidine isethionate, chlorhexidine hydrochloride, hexetidine, Quaternium 15, triclocarbon, polyhexamethylene biguanide, cetylpyridinium chloride, imidazolidinyl urea, diazolidinyl urea, 3-yo Do-2-propynyl-N-butylcarbamate, 2-methyl-4-isothiazolin-3-one, dimethyl hydantoin, 5-chloro-2- (2,4-dichlorophenoxy) phenol, glyceryl monolaurate Lauric acid, Camellia sinensis, Candida bon bicola / glucose / rapeseed oil fatty acid methyl fermented product, hydrogen peroxide, phenol, poloxamer 188, polyvinylpyrrolidone-iodo, thiourea, cinnamon oil, cinnamaldehyde, lemongrass oil, clove oil, Saw Palmetto Extract, White Thyme Oil, Red Thyme Oil, Thymol, Tea Tree Oil, Pine Spina Star Bark Extract, Rosemary Leaf Extract, Grape Seed Extract, Betel Oil and other Natural Antibacterial Agents, Silver Nitrate , Silver lactate, silver citrate, silver Mention may be made of silver-containing compounds such as oleite, antimicrobial fatty acid esters of polyhydric alcohols, fatty ethers of polyhydric alcohols and their alkoxylated derivatives, and combinations thereof.

  In one embodiment, from about 0.001 wt% to about 10 wt%, such as from about 0.01 wt% to about 5 wt%, or from about 0.05 wt% to about 2 wt%, based on the total weight of the composition.

  In one embodiment, the antimicrobial agent is an antifungal agent such as an azole. Examples include but are not limited to miconazole, ketoconazole, econazole, itraconazole, sertaconazole, fluconazole, voriconazole, clioquinol, bifoconazole, terconazole, butconazole, thioconazole, oxyconazole, sulconazole, saperconazole ( saperconazole), clotrimazole, undecylenic acid, haloprozin, butenafine, tolnaftate, nystatin, cyclopyroxolamine, terbinafine, amorolfine, naphthifine, elubiol, griseofulvin, their surface acceptable salts, and these Combinations can be mentioned.

  In one embodiment, the antimicrobial agent is an antibiotic or disinfectant. Examples include, but are not limited to, mupirocin, neomycin sulfate, bacitracin, polymyxin B, 1-ofloxacin, tetracyclines such as chlortetracycline hydrochloride, -10-oxytetracycline hydrochloride, and tetracycline hydrochloride, clindamycin phosphate, Mention may be made of gentamicin sulfate, metronidazole, hexyl resorcinol, methylbenzethonium chloride, phenol, quaternary ammonium compounds, tea tree oil, and combinations thereof.

  In one embodiment, the composition of the invention comprises an “anti-psoriatic agent”. Examples of anti-psoriatic agents include, but are not limited to, corticosteroids (e.g., betamethasone dipropionate, betamethasone valerate, clobetasol propionate, diflorazone acetate, halobetasol propionate, triamcinonide, dexamethasone, fluocinonide, Ocinolone acetonide, harsinonide, triamcinolone acetate, hydrocortisone, hydrocortisone valerate (hydrocortisone verlerate), hydrocortisone butyrate, acromethasone dipropionate, fludroxycortide, mometasone furoate, and methylprednisolone acetate, methotrexate acetate , Calcipotriene, anthraline, shale oil, elubiol, ketoconazole, coal tar, sari Le acid, zinc pyrithione, may be mentioned selenium sulfide, hydrocortisone, sulfur, menthol, pramoxine hydrochloride, and combinations thereof.

  In one embodiment, the composition of the invention comprises an “antiviral agent”. Examples of antiviral agents include, but are not limited to, imiquimod, podofilox, podophylline, interferon alfa, acyclovir, famcyclovir, falacyclovir, valcyclovir, reticulos, and cidofovir Can be mentioned.

  In one embodiment, the composition of the invention comprises an “anti-inflammatory agent”. Anti-inflammatory agents include non-steroidal anti-inflammatory agents and steroidal anti-inflammatory agents. Examples of steroidal anti-inflammatory agents include, but are not limited to, hydrocortisone, hydroxyltriamcinolone alphamethyldexamethasone, dexamethasone phosphate, beclomethasone dipropionate, clobetasol valerate, desonide, desoxymethasone, desoxymethasacetate Corticosterone, dexamethasone, dichlorizone, diflorazone acetate, diflucortron valerate, fluadrenolone, fluclarolone acetonide, fluclarolone, fludrocortisone, flumetholone pivalate, fluocinolone acetonide, fluocinonide, flucononide Flucortine butylester, fluocortron, fluprednidene acetate (fluprednylidene) acetate, fluland renoro Halsinonide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone acetonide, cortisone, cortodoxone, flucetonide, fludrocortisone, difluorosone diacetate, fluradrenalone acetonide, fluradrenalone aceton (Amciafel), amcinafide, betamethasone, chlorprednisone, chlorprednisone acetate, crocortelone, clescinolone, dichlorizone, difluprednate, flucloronide, flunisolide, fluoromethalone, fluoromethalone Fluperolone, fluprednisolone, hydrocortisone valerate, hydrocortisone cyclopentylpropionate (hydrocort isone cyclopentylproprionate), hydrocortamate, meprednisone, parameterzone, prednisolone, prednisone, beclomethasone dipropionate, betamethasone dipropionate, triamcinolone, and combinations thereof. Examples of non-steroidal anti-inflammatory agents include, but are not limited to, immunosuppressants such as COX inhibitors, LOX inhibitors, p38 kinase inhibitors, cyclosporine and cytokine synthesis inhibitors. Other natural anti-inflammatory agents can include, but are not limited to, chamomile, soy or oat extracts, beta-glucan, and totarol.

Other effective agents include, but are not limited to, calcium alginate, collagen, recombinant human platelet derived growth factor (PDGF), other growth factors, ketanserin, iloprost, prostaglandin E ₁ , and hyaluronic acid Mention may be made of wound healing promoters, scar reducing agents such as mannose-6-phosphate, analgesics, wound cleansing agents such as papain, enzymatic wound cleansing agents, and anesthetics such as lidocaine and benzocaine. In one embodiment, the composition comprises menthol, camphor, antihistamine, or tetracaine, lidocaine, prilocaine, benzocaine, bupivacaine, mepivacaine, dibucaine, etidocaine, butakine, cyclomethicaine, hexylcaine, proparacaine, and lopivacaine. A local anesthetic and one or more capsaicin or oatmeal.

  In one embodiment, the amount of anti-inflammatory agent, antiviral agent, anti-psoriatic agent, and / or other effective agent included in the composition is about 0.001 wt% to about about 1 wt% relative to the total weight of the composition. 10 wt%, such as from about 0.01 wt% to about 5 wt%, or from about 0.05 wt% to about 2 wt%.

  The composition of the present invention further comprises lactate. Examples of lactate include, but are not limited to, C2-C22 lactate such as cetyl lactic acid and C2-C35 lactate such as C12-C15 lactate. The amount of lactate contained in the composition of the present invention is about 0.1 to about 0.1 wt% to about 20 wt%, or about 1 wt% to about 10 wt%, for example, relative to the total weight of the composition. % To about 50%.

  In one embodiment, the composition of the present invention further comprises a phospholipid. Phospholipids include synthetic phospholipids and natural phospholipids. Examples of such phospholipids include, but are not limited to, cocamidopropyl PG-dimonium chloride (Collapid C ™) (Colonial Chemical, Inc., South Pittsburgh, Tennessee, USA) Stearamidopropyl PG-dimonium chloride (Collapid ST ™), sunflower amide propyl phosphate PG-dimonium chloride (Collipidid SUN ™), olivamidpropyl sodium PG-dimonium chloride (Collapid OL ( ), Sodium grape seed amidopropyl PG-dimonium chloride (Collipid GS ™), linoleamidopropyl PG-dimonium chloride (Collipid SAFEL ( Standard)), PEG-8 dimethicone sunflower amidopropyl PG-dimonium complex (Collalipid SIL ™), ricinolamidopropyl PG-dimonium chloride (Collipid RC ™), sodium palm PG-dimonium chloride Phosphoric acid (Arlasilk ™ phospholipid CDM) (Uniqema, ICI Group of Comapnies, Wilton, UK), cocamidopropyl PG dimonium chloride (Arlasilk ™ phospholipid PTC), stearamide propyl PG-dimonium chloridolinic acid (Arlasilk ™ phospholipid SV), linoleamidopropyl PG-dimonium chloridolinic acid (Arlasilk ™ phospholipid EFA), linoleamidopropyl PG-dimemo Dimethicone nium chloride (Arlasilk ™ phospholipid PLN), myristamidopropyl PG-dimonium chloride (Arlasilk ™ phospholipid PTM), sodium boridiamidopropyl PG-dimonium chloride (Arlasilk ™) And phospholipids composed of diester phospholipids and triester phospholipids such as phospholipid GLA) and combinations thereof.

  In one embodiment, the composition comprises a “sebum admixture”. The sebum admixture is a drug that is mixed with sebum in the assay described below. Artificial sebum is described on page 79 (Table 5.4) of the chapter “Effects of skin surface lipids in topical preparations” by Obsorne and Hatzenbuhler (D. Osborne (D Osborne and A. Amann, “Topical Drug Delivery Formulation”, Marcel Dekker, Inc., New York, 1990, p 69-85). Artificial sebum is a white waxy substance at room temperature. 50 μl of sebum was precipitated into a clear 200 μl vial using a precision micropipette. Then 100 μl of reagent was added to the vial. The vial was warmed at 32 ° C. and observed after 8 hours with reference. When the drug is mixed with sebum, the sebum becomes transparent.

  Examples of sebum admixtures include, but are not limited to, aromatic alcohols such as phenyl alcohol having a chemical structure of C6H5-R (OH) (R is an aliphatic radical) such as benzyl alcohol and phenethyl alcohol, ethylene glycol Aromatic glycol ethers such as phenyl ether, propylene glycol methyl ether and propylene oxide or butylene oxide glycol ethers as disclosed in US Pat. No. 5,133,967, fatty acids, and linoleic acid, linolenic acid, Polyunsaturated fatty acids such as stearidonic acid, plants rich in essential fatty acids, fruits, or marine extracts, or, but not limited to, blueberry (bilberry) seed oil, giant whiteberry (cranberry) seeds Oil, cowberry (phosphorus) Berry seed oil, European strawberry (raspberry) seed oil, Holomui strawberry (cloudberry) seed oil, black currant (black currant) seed oil, sunjigumi (sea buckthorn) seed oil, shazen murasaki (echium) seed oil, barley (burley) ) Polyunsaturated fatty acids such as seed oil, birch bud extract, saw palmetto extract, borage oil, evening primrose oil, witch hazel extract, and soybean oil, and cetyl ocenate, isostearyl benzoate, pentaerythro Mention may be made of pentaerythiol teraoctenate, methyl gluces, tocopherol acetate, benzalkonium chloride, benzethonium chloride, and combinations thereof.

  The composition of the present invention may also contain an alcohol. Examples of suitable alcohols include, but are not limited to, ethyl alcohol. In one embodiment, the composition is, for example, from about 0.01 wt% to about 40 wt%, specifically from about 0.1 wt% to about 30 wt%, or from about 1 wt% to about 20 wt%, etc., relative to its total weight As shown in FIG.

  In one embodiment, the composition includes a nonionic surfactant. Examples of non-ionic surfactants are “International Cosmetic Ingredient Dictionary and Handbook” (Washington DC Cosmetics), edited by Wenninger and McEwen. • The 2nd edition of The Cosmetic, Toiletry, and Fragrance Assoc., 9th edition, 2002, hereinafter referred to as “CTFA Handbook”.

  In one embodiment, the composition includes a whitening agent. Examples of whitening agents include, but are not limited to, retinoids such as retinol, soy or licorice extracts, tyrosine inhibitors such as hydroquinone, ascorbic acid glucoside, oxalic acid, calcium D-pantethein-S-sulfonate, arbutin, Mention may be made of magnesium ascorbate phosphate, pantothiol, dihydrolipoic acid, and arlatone.

  In one embodiment, the composition of the present invention has a pH greater than about 2, such as less than about pH 10, such as less than about pH 7.0 or less than about 4.5.

  Topical compositions useful in the present invention include formulations suitable for topical application to the skin. The composition can further comprise a topically acceptable topical carrier. A topically acceptable topical carrier can comprise from about 50 wt% to about 99% of the composition (eg, from about 80 wt% to about 95 wt% of the composition).

  The composition includes, but is not limited to, lotions, creams, gels, sticks, sprays, shaving creams, ointments, cleansing liquids and solid bars, pastes, powders, mousses, masks, peels, makeups, and wipes. Can be a variety of products including solid or liquid compositions. Such products include various types of superficially acceptable topical carriers, including but not limited to solutions, emulsions (eg, microemulsions and nanoemulsions), gels, solids, and liposomes. Can be included. The composition can be used with other devices such as skin polishing devices, skin massagers, electronic stimulators, phototherapy devices, ultrasound devices, radio frequency devices, heating / cooling devices, and micro-osmosis devices. The carriers shown below are not intended to be limiting. One skilled in the art should be able to formulate other carriers.

  Topical compositions useful in the present invention can be formulated as solutions. Solutions typically comprise an aqueous solvent (eg, from about 50% to about 99% or from about 90% to about 95% of a surface acceptable aqueous solvent).

  A topical composition useful in the present invention can be formulated as a solution containing an emollient. Such compositions preferably contain from about 2% to about 50% of the emollient. As used herein, “emollient” refers to a substance used to prevent or reduce skin dryness and protect the skin. A variety of suitable emollients are known and can be used in the present invention. See the CTFA handbooks p1656 to 1661, 1626, and 1654 to 1655 where various suitable materials are shown.

  Lotions can be formulated from such solutions. Lotions typically contain about 1% to about 20% (eg, about 5% to about 10%) emollient and about 50% to about 90% (about 60% to about 80%) water.

  Creams can also be formulated from solutions. Creams typically contain from about 5% to about 50% (eg, from about 10% to about 20%) emollients and from about 45% to about 85% (eg, from about 50% to about 75%) water.

  Ointments can also be formulated from solutions. Ointments can contain animal oils, vegetable oils, or semi-solid hydrocarbons as merely a base. The ointment can include from about 2% to about 10% of the emollient and from about 0.1% to about 2% of the thickener. For details of the thickeners or viscosity increasing agents useful in the present invention, see the CTFA Handbook, p1693-1697.

  Topical compositions useful in the present invention can be formulated as emulsions. When the carrier is an emulsion, the carrier contains about 1% to about 10% (eg, about 2% to about 5%) of an emulsifier. The emulsifier can be nonionic, cationic, or anionic. Suitable emulsifiers are described in, for example, p1673-1686 of the CTFA handbook.

  Lotions and creams can be formulated as emulsions. Such lotions typically contain 0.5% to about 5% of an emulsifier. Such creams have an emollient of about 1% to about 20% (eg, about 5% to about 10%), water of about 20% to about 80% (eg, about 30% to about 70%), Contains about 1% to about 10% of an emulsifier (eg, about 2% to about 5%).

  Single-phase emulsion skin preparations such as oil-in-water and water-in-oil lotions and creams are well known in the field of cosmetics and are useful in the present invention. A multiphase emulsion composition such as W / O / W type, which is a composite type of oil-in-water type and water-in-oil type, is also useful in the present invention. In general, such single-phase and multi-phase emulsions contain water, emollients, and emulsifiers as essential ingredients.

  The topical composition of the present invention can also be formulated as a gel (for example, an aqueous gel using a suitable gelling agent). Examples of suitable gelling agents for aqueous gels include, but are not limited to, natural rubber, acrylic acid and acrylic acid polymers and copolymers, and cellulose derivatives such as hydroxymethylcellulose and hydroxypropylcellulose. . Examples of gelling agents suitable for oils (eg, mineral oils) include, but are not limited to, hydrogenated butylene / ethylene / styrene copolymers and hydrogenated ethylene / propylene / styrene copolymers. Such gels typically contain from about 0.1 wt% to about 5 wt% of such a gelling agent.

  In one embodiment, the composition is anhydrous. In one embodiment, such anhydrous compositions are exothermic upon application.

  The topical compositions of the present invention can also be formulated into solid formulations (eg, wax-based sticks, soap bar compositions, powders, wipes containing powders, or bandages).

  In addition to the components described above, the topical compositions useful in the present invention can include various oil-soluble and water-soluble substances used in established compositions conventionally used on the skin.

  The topical composition may be applied as often as necessary or as part of a normal dosing schedule, with a frequency of once a week to several times a day (eg, twice a day). The dose will depend on factors such as the age and physical condition of the user, the duration of treatment, the type of compound, product or composition used, and the type of superficially acceptable carrier used.

  Several examples are shown below. The present invention is not limited to these details.

Example 1
A composition of the present invention (pH = 3.7) was prepared by first dissolving salicylic acid in ethanol, then adding the remaining ingredients listed in Table 1, and then mixing the mixture with a homogenizer until homogeneous.

Example 2
A composition of the present invention (pH = 3.7) was prepared in the same manner as in Example 1.

Example 3
A composition of the present invention (pH = 3.7) was prepared by mixing the components listed in Table 3 below. First, the first premix ingredients were mixed and then the mixture was mixed with the Stage B ingredients until homogeneous. Stage A ingredients were also mixed until homogeneous. The stage B mixture was then added and mixed until homogeneous. After-addition ingredients and a second premix were added to the resulting emulsion and mixed until homogeneous.

Example 4
A composition of the present invention (pH = 3.7) was prepared by mixing the ingredients listed in Table 4 below in the same manner as described in Example 3.

Example 5
A composition of the present invention (pH = 3.7) was prepared by mixing the ingredients listed in Table 5.

In stage B, water was heated to 40 ° C. and all other ingredients were added, mixed and dissolved. The stage A ingredients were then mixed until homogeneous. Stage A was added to Stage B and mixed until homogeneous. Subsequently, post-added components were added.

Example 6
A clinical examination of mild to moderate acne treatment was performed using the composition of Example 4. This clinical test demonstrated that acne can be treated quickly with the composition of the present invention (product applied to the acne portion twice a day). This clinical test included a control composition of Clearasil® acne treatment cream (Boots International Inc., London, UK) containing 10% benzoyl peroxide (10% BPO) and no treatment Acne population was also used. Acne severity was graded according to the following scale (recommended by the American academy of dermatology).

Table 6 shows the results of clinical tests on mild to severe patients (reference grades 3 to 5).

  The improvement of the pimple size, redness, and ridge criteria for mild acne lesions was superior to the formulation of Example 4 compared to 10% BPO. In addition, the preparation of the present invention was less peeled off.

Table 7 shows the results of clinical tests on acne patients with medium to severe (base grade 4-5) acne patients with deep roots. The formulation of Example 4 showed a surprisingly good effect on all treatments of moderate to severe acne compared to untreated controls and 10% BPO cream.

  The composition of the present invention provides for the size of the pimples without moderate irritation to the skin, dryness, and noticeable scarring and post-treatment pigmentation for moderate to severe acne, where the roots of the puffs are usually deeper, It showed a dramatic improvement in terms of redness, bumps, and flaking.

Example 7
A clinical study was conducted over a week to evaluate the rapid effect of the formulation of Example 4 on Clearsil® acne treatment cream in the treatment of mild to moderate acne. This clinical test was a double blind test involving application to the entire face twice a day. The patients were men and women between the ages of 12 and 30 whose Fiztpatrick Skin Type was I-IV. The patient's acne was mild to moderate at the baseline visit and included 1-3 active target inflammatory lesions.

  Clinical evaluation of target lesions by dermatologists showed a statistically significant reduction in erythema in acne target lesions treated with the formulation of Example 4 in as little as 4 hours after treatment. Specifically, after 8 hours, the diameter of the target lesion began to shrink significantly, and on the second day the lesion height / ridge was significantly reduced and maintained over time. 10% BPO showed no significant effect after 4 hours, statistics of target lesion erythema at 8 hours and lesion diameter at 1 week with Example 4 and 10% BPO treatment cream Significant differences occur, indicating that the formulations of the present invention are more effective. Patients using Example 4 did not see any increase in skin irritation parameters (peeling, edema, erythema, burning pain, irritation pain, itching) as assessed by the dermatologist or patient. Also, a statistically significant decrease in flaking and sebum was confirmed by dermatologists, and a significant decrease in itchiness and tightness with respect to criteria at various time points was confirmed by patients.

  In patients using Example 4, unlike patients using 10% BPO treatment, peeling began to decrease significantly after 4 hours, starting from day 1 with a marked decrease in sebum and dryness, and the duration of the study. Continued. In contrast, patients using 10% BPO cream showed a statistically significant increase in sebum at day 2.

Example 8
Two formulations containing 0.10% histamine were prepared according to the following table.

Male patients were selected to evaluate in vivo delivery of histamine with these two formulations. Both formulations were shaken and 0.05 mL of solution was dispensed and applied to the same size marked area on both sides of the patient's nose. Sensation and appearance were recorded. Typical histamine effects, erythema, itching and mild burning pain were observed in both formulations. The formulation in Table 8b (containing _C12-15 alkyl lactate) showed a visible reaction in less than 2 minutes and peaked in about 5 minutes. The formulation of Table 8a (without C _12-15 alkyl lactate) had such a visible effect of histamine only after 5 minutes and peaked at about 10-15 minutes. The formulations in Table 8b caused itching sensations that persisted for over an hour, considerably longer than the 35 to 40 minute response of the formulations in Table 8a.

Example 9
Another composition was prepared using the components in Table 9a shown below.

  This composition was prepared as follows. First, dipropylene glycol isoceteth-20 acetate (Dipropylene Glycol Isocetheth-20 Acetate) was placed in a beaker A and heated to 40 ° C. to melt. In beaker B, ethyl alcohol and salicylic acid were added and mixed. In a beaker C, deionized water and hydroxyethyl cellulose were mixed and heated to 35 ° C. to 40 ° C. with stirring to be homogeneous. The composition was then cooled to room temperature. After cooling, the contents of beaker B were placed in beaker C and stirred until homogeneous. While stirring, witch-hazel, glycerin, phenoxyethanol, benzalkonium chloride, and propylene glycol were added in order.

  Cyclopentasiloxane, polysorbate 20, phenethyl dimethicone, fragrance, C12-15 alkyl lactate, cetyl lactate, and palm oil alkyl PG dimonium chloride chloride (Sodium Coco PG-Dimonium Chloride Phosphate) were then added to beaker A. The contents of beaker A were then added to beaker C and the resulting composition was mixed until homogeneous. The pH of this homogeneous composition was then adjusted to the range of 3.5-4.0 with 20% sodium hydroxide. A mixture of polyacrylamide, C13-14 isoparaffin, and laureth 7 was then added and mixed until homogeneous. The final product was then packaged in 1-ounce tubes.

  1-ounce tubes were distributed to men and women aged 12-30 years with Fiztpatrick Skin Types I-IV. Patients were instructed to wash their face every morning and evening at PURPOSE® Gentle Cleaning Wash (Johnson & Johnson Consumer Products Company, Skillman, NJ). The patient was also instructed to push the final product in the amount of (US) 5 cents coins onto the finger and apply it to the entire face except the eyes, lips and mouth. Each patient was instructed not to wash her face for at least 3 hours after applying the final product.

Patients were given self-assessment questionnaires to fill in at the start of the study, one week later, two weeks later, five weeks later, and six weeks later. Table 9b below shows the symptoms at these time points and the state felt by the patient. The rating is 1 to 10, with 1 being the lowest and 10 being the highest. All results are normalized to week 0, so each number shows a change from baseline. Positive numbers indicate improvement.

The benefits assessment questionnaire was handed to the patient to complete along with the self-assessment questionnaire. Table 9c below shows the benefits and patient feelings at the time listed. Shown on a scale of 1-5, 1 indicates that the patient has not agreed at all, and 5 indicates that the patient has fully agreed. Table 9c shows the percentage that the patient gave the benefit 4 (generally agreed) or 5 (completely agreed).

International standard acne parameter grading by experts was performed at week 1, week 2, week 5, and week 6. Expert grading was done in a room with constant light conditions during the examination. Because this test is a double-blind test, neither the examiner nor the patient was informed of what treatment was applied to the patient. The severity was divided into 0-4 grades. 0 is mildest with no acne and 4 is the most severe. A decrease in value over time indicates an improvement. This result is shown in Table 9d.

  Although the invention has been described using detailed descriptions thereof, it is to be understood that the detailed descriptions are not intended to limit the scope of the invention as defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the appended claims.

Embodiments of the present invention are as follows.
(1) A composition comprising an anti-acne agent, an antibacterial agent, and lactate.
(2) The anti-acne agent is selected from the group consisting of salicylic acid, benzoyl peroxide, sulfur, retinoic acid, azelaic acid, clindamycin, adapalene, erythromycin, sulfacetamide sodium, and combinations thereof. A composition according to embodiment (1), characterized.
(3) The antibacterial agent is benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, 3-iodo-2-propynyl-N-butylcarbamate, hexetidine (5-amino-1,3-bis- (2-ethylhexyl) Embodiments (1) and (2), wherein the composition is selected from the group consisting of -5-methyl-hexahydropyrimidine), quaternium-15 triclosan, chlorhexidine digluconate, and combinations thereof.
(4) The composition according to embodiment (1)-(3), wherein the lactate salt is selected from the group consisting of C ₁₂ -C ₁₆ alkyl lactate and combinations thereof.
(5) The composition according to any one of the embodiments (1) to (4), wherein the composition further contains a phospholipid.

(6) The phospholipid is coconut oil alkyl PG dimonium chloride phosphate (Sodium Coco PG-Dimonium Chloride Phosphate), cocamidopropyl PG dimonium chloride, or myristamidopropyl PG dimonium chloride A composition according to embodiment (5), characterized in that
(7) A method for treating follicular disease,
Applying a composition comprising an anti-acne agent, an antibacterial agent and lactate to the affected area of the skin in need of treatment.
(8) The method according to embodiment (7), wherein the hair follicle disease is acne, rosacea, or seborrhea.
(9) The method according to embodiment (8), wherein the method for treating acne includes treating a pimple before appearance.
(10) The method according to embodiment (9), wherein the method for treating acne includes a step of treating a black head.

(11) The method according to embodiment (10), wherein the appearance of acne is shortened within about 8 hours.
(12) A method for making skin pores or sebum inconspicuous,
Applying a composition comprising an anti-acne agent, an antibacterial agent and lactate to the affected area of the skin in need of treatment.
(13) A method for adjusting the skin tone or smoothing the skin,
Applying a composition comprising an anti-acne agent, an antibacterial agent and lactate to the affected area of the skin in need of treatment.
(14) The method according to embodiment (12), wherein the skin has freckles, post-inflammatory pigmentation (PIH), or scarring.
(15) The antibacterial agent is benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, 3-iodo-2-propynyl-N-butylcarbamate, hexetidine (5-amino-1,3-bis- (2-ethylhexyl) -5-methyl-hexahydropyrimidine), quaternium-15 triclosan, chlorhexidine digluconate, and combinations thereof, The method according to embodiment (7)-(14).

(16) The composition according to embodiments (7)-(15), wherein the lactate salt is selected from the group consisting of C12-C16 alkyl lactate and combinations thereof.
(17) The composition according to any one of embodiments (7) to (16), wherein the composition further contains a phospholipid.
(18) The phospholipid is coconut oil alkyl PG dimonium chloride phosphate (Sodium Coco PG-Dimonium Chloride Phosphate), cocamidopropyl PG dimonium chloride, or myristamidopropyl PG dimonium chloride A composition according to embodiment (17), characterized in that

Claims (7)

  A composition comprising an anti-acne agent, an antibacterial agent, and lactate.   The anti-acne agent is selected from the group consisting of salicylic acid, benzoyl peroxide, sulfur, retinoic acid, azelaic acid, clindamycin, adapalene, erythromycin, sodium sulfacetamide, and combinations thereof The composition of claim 1.   The antibacterial agent is benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, 3-iodo-2-propynyl-N-butylcarbamate, hexetidine (5-amino-1,3-bis- (2-ethylhexyl) -5- The composition of claims 1 and 2, wherein the composition is selected from the group consisting of methyl-hexahydropyrimidine), quaternium-15 triclosan, chlorhexidine digluconate, and combinations thereof. The lactate, C ₁₂ -C ₁₆ alkyl lactate and compositions according to claim 1-3, characterized in that it is selected from the group consisting of combinations.   The composition according to claim 1, further comprising a phospholipid.   The phospholipid is coconut oil alkyl PG dimonium chloride chloride (Sodium Coco PG-Dimonium Chloride Phosphate), cocamidopropyl PG dimonium chloride, or myristamidopropyl PG dimonium chloride The composition according to claim 5. A method of treating hair follicle disease,
Applying a composition comprising an anti-acne agent, an antibacterial agent and lactate to the affected area of the skin in need of treatment.